VYNE VYNE Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VYNE

Price (delayed)

$0.509

Market cap

$16.98M

P/E Ratio

N/A

Dividend/share

$0.4

EPS

-$0.49

Enterprise value

-$7.65M

?
Relative Growth: Rel. Growth: 31
Relative Strength: Rel. Strength: 26
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 37

VYNE's mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.

Highlights
VYNE's debt has dropped by 100% year-on-year
VYNE Therapeutics's quick ratio has surged by 67% QoQ
VYNE's equity is down by 44% year-on-year and by 11% since the previous quarter
VYNE's gross profit is down by 25% YoY and by 20% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://vynetherapeutics.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of VYNE

VYNE stock price

How has the VYNE Therapeutics stock price performed over time
Intraday
-44.88%
1 week
-33.11%
1 month
-21.76%
1 year
-62.01%
YTD
-12.26%
QTD
-21.78%

Financial performance

How have VYNE Therapeutics's revenue and profit performed over time
Revenue
$454,000
Gross profit
$454,000
Operating income
-$24.37M
Net income
-$21.46M
Gross margin
100%
Net margin
-4,726.2%
The net income has increased by 49% YoY and by 19% from the previous quarter
VYNE Therapeutics's operating income has increased by 46% YoY and by 18% from the previous quarter
VYNE's net margin is up by 32% year-on-year
VYNE's operating margin is up by 29% year-on-year but it is down by 2.8% since the previous quarter

Price vs fundamentals

How does VYNE's price correlate with its fundamentals

Growth

What is VYNE Therapeutics's growth rate over time

Valuation

What is VYNE Therapeutics stock price valuation
P/E
N/A
P/B
0.69
P/S
47.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-16.86
VYNE's EPS has soared by 51% YoY and by 21% QoQ
VYNE's equity is down by 44% year-on-year and by 11% since the previous quarter
VYNE's P/B is 15% above its 5-year quarterly average of 0.6 and 15% above its last 4 quarters average of 0.6
VYNE's P/S is 45% below its 5-year quarterly average of 86.7 and 30% below its last 4 quarters average of 68.9
The revenue has declined by 25% year-on-year and by 20% since the previous quarter

Efficiency

How efficient is VYNE Therapeutics business performance
VYNE's return on invested capital has dropped by 115% year-on-year and by 20% since the previous quarter
VYNE's ROS is up by 32% YoY
The ROE rose by 6% QoQ and by 3.2% YoY
The ROA has contracted by 6% YoY

Dividends

What is VYNE's dividend history
DPS
$0.4
Dividend yield
78.98%
Payout ratio
N/A
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did VYNE Therapeutics financials performed over time
VYNE's total liabilities has dropped by 90% year-on-year and by 48% since the previous quarter
VYNE Therapeutics's quick ratio has surged by 67% QoQ
VYNE's debt is 100% smaller than its equity
VYNE's debt has dropped by 100% year-on-year
VYNE's equity is down by 44% year-on-year and by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.